Associated Papers
Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer.
Bekos C et al.
Journal of Personalized Medicine, 2021
BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile.
Alvarez C et al.
Oncotarget, 2017
Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.
Ossa CA et al.
The Oncologist, 2016
The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective.
Dutil J et al.
Breast Cancer Research and Treatment, 2015
26564481 (PubMed )
Supplement: 10549_2015_3629_MOESM2_ESM.xlsx › Nomenclature_of_variants
Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families.
Gonzalez-Hormazabal P et al.
Breast Cancer Research and Treatment, 2011
Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M et al.
Breast Cancer Research and Treatment, 2006
Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors.
Tapia T et al.
Epigenetics, 0
Select a paper to view details